Major depressive disorder psychotherapy

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mitra Chitsazan, M.D.[2] Aiden Nguyen[3]

Overview

Structured, time-limited, manualized psychotherapy is a first-line treatment for major depressive disorder (MDD) across the severity spectrum. Cognitive behavioral therapy (CBT) monotherapy is suggested for mild MDD. Monotherapy with either CBT or a second-generation antidepressant is recommended for moderate to severe MDD, and combined psychotherapy and pharmacotherapy is suggested for severe, chronic, or recurrent MDD. Head-to-head comparisons show no reliable difference among the guideline-endorsed psychotherapies for MDD in depressive symptoms or remission. Psychotherapy has efficacy similar to second-generation antidepressants in the acute phase of MDD, and its benefit is more durable than that of medication discontinued after acute response.

Types of Psychotherapies

Psychotherapy

Evidence-Based Psychotherapies

The VA/DoD 2022 guideline suggests offering one of the following psychotherapies for MDD, not rank-ordered, according to patient preference (Weak for).[1][2]

Psychotherapy Focus / notes
Cognitive behavioral therapy (CBT) Targets maladaptive cognitions and behaviors. Best studied and most widely available.
Behavioral activation (BA) Increases engagement in reinforcing, value-driven activities. Among the largest effect sizes vs usual care.
Interpersonal psychotherapy (IPT) Role transitions, grief, interpersonal disputes and deficits.
Problem-solving therapy (PST) Structured problem-solving skills. Well suited to primary care.
Mindfulness-based cognitive therapy (MBCT) 8-week program. Strongest role in relapse prevention.
Acceptance and commitment therapy (ACT) "Third-wave" approach targeting psychological flexibility.
Short-term psychodynamic psychotherapy (STPP) Added as a first-line option in 2022 based on two noninferiority RCTs vs CBT.
  • In MDD, no single psychotherapy is superior for depressive symptoms or remission, and no specific CBT variant (e.g., metacognitive therapy, cognitive evolutionary therapy) outperforms traditional CBT.[1][3]
  • A network meta-analysis found six specific psychotherapies (cognitive/CBT, BA, IPT, PST, STPP, mindfulness-based) similarly more efficacious than usual care, all with at least medium effect sizes. Response rates were about 50% with psychotherapy vs about 25% without. Non-directive supportive counseling had smaller benefit.[4][5]
  • Third-wave therapies (ACT, MBCT) did not differ from other psychotherapies in the network meta-analysis above.[4] In the ACP network meta-analysis, low-certainty evidence suggested third-wave CBT may have higher response and remission than antidepressants; results should be interpreted cautiously.[6]

Selection by Severity

The selection of psychotherapy for MDD is guided by severity as follows.

Severity Guideline recommendation
Mild (PHQ-9 <10) CBT monotherapy suggested (conditional; low-certainty evidence).[7] Psychotherapy is generally preferred over antidepressants, which are usually not indicated.[5] Specific psychotherapies outperform usual care even in mild depression.[5]
Moderate to severe (PHQ-9 ≥10) Monotherapy with either CBT or a second-generation antidepressant (SGA) (strong; moderate-certainty). Combination CBT + SGA suggested as an option (conditional; low-certainty).[7]
Severe, chronic (>2 years), or recurrent (≥3 episodes) VA/DoD suggests offering combined pharmacotherapy + evidence-based psychotherapy (Weak for).[1] The JAMA 2024 review recommends combined treatment for PHQ-9 ≥15.[5]

Combined and Sequential Treatment

  • Acute combination: In MDD, a network meta-analysis cited in JAMA found combined treatment superior to psychotherapy alone and medication alone. Response was about 65% with combination vs about 50% with monotherapy. The advantage is greatest in more severe or chronic depression.[5]
  • Sustained response: Psychotherapy or combined treatment yields more sustained response through 12 months than medication alone.[5]
  • Partial response to medication: Adding CBT in patients with residual symptoms after adequate pharmacotherapy improves symptoms and remission vs continued pharmacotherapy alone.[1]
  • Sequential approach: Psychotherapy delivered in the residual/continuation phase after acute pharmacologic response reduces relapse and recurrence and can facilitate medication tapering.[8]

Relapse Prevention

  • In MDD, MBCT, CBT, and IPT are suggested for patients at elevated risk of relapse after remission.[1] MBCT is best established for recurrence prevention and was originally studied in patients with ≥3 prior episodes.[9] An individual patient-data meta-analysis found that MBCT benefit was not restricted by number of prior episodes and was greatest in patients with higher residual symptoms.[10]
  • Psychotherapy during the continuation phase reduces residual symptoms and relapse risk across a broad range of patients.[3]
  • Combining CBT with antidepressants raises acute recovery but may, in some patients, blunt CBT's enduring protective effect after treatment ends; this is under study.[11]

Format and Delivery

  • Individual vs group: Outcomes of psychotherapy for MDD are comparable overall; choose by patient preference.[1] The Lancet 2026 Seminar notes that CBT and BA may produce greater symptom reduction in group settings for less-severe depression, whereas individual sessions are more effective in more-severe depression.[3]
  • Digital/remote: Computer-, internet-, and telephone-delivered psychotherapies have demonstrated efficacy and may be used when in-person access is limited.[12] Guided (therapist-supported) self-help has effectiveness comparable to individual, group, and telephone CBT, whereas unguided self-help is less effective (no better than usual care) and has lower acceptability.[13]
  • Do not mix components: No evidence supports combining elements of different psychotherapy approaches.[1]
  • Fallback option: Non-directive supportive therapy is a reasonable alternative for patients who decline first-line evidence-based psychotherapies, with small benefit over no treatment (low-certainty evidence).[1]

Monitoring and Escalation

  • In MDD, reassess at least monthly after starting or changing treatment until remission, using a validated scale (e.g., PHQ-9) and reviewing adherence and adverse effects.[1]
  • If there is no substantive improvement after about 6 weeks of an adequate psychotherapy trial, consider switching psychotherapy type, adding pharmacotherapy, or psychiatric consultation.[12]
  • If psychotherapy alone fails, consider adding an antidepressant. If medication alone fails, options include adding psychotherapy, switching, or augmenting.[5]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Department of Veterans Affairs/Department of Defense. Management of Major Depressive Disorder (MDD). Clinical Practice Guideline. 2022.
  2. ↑ McQuaid JR, Buelt A, Capaldi V; et al. (2022). "The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline". Ann Intern Med. 175 (10): 1440–1451. doi:10.7326/M22-1603.
  3. ↑ 3.0 3.1 3.2 Malhi GS, Bell E, Stavdal A; et al. (2026). "Depression". Lancet. 407 (10540): 1738–1756. doi:10.1016/S0140-6736(26)00201-1.
  4. ↑ 4.0 4.1 Cuijpers P, Quero S, Noma H; et al. (2021). "Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types". World Psychiatry. 20 (2): 283–293. doi:10.1002/wps.20860.
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Simon GE, Moise N, Mohr DC (2024). "Management of Depression in Adults: A Review". JAMA. 332 (2): 141–152. doi:10.1001/jama.2024.5756.
  6. ↑ Gartlehner G, Dobrescu A, Chapman A; et al. (2023). "Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis for a Clinical Guideline by the American College of Physicians". Ann Intern Med. 176 (2): 196–211. doi:10.7326/M22-1845.
  7. ↑ 7.0 7.1 Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I; et al. (2023). "Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians". Ann Intern Med. 176 (2): 239–252. doi:10.7326/M22-2056.
  8. ↑ Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021.
  9. ↑ Seshadri A, Orth SS, Adaji A, et al. Mindfulness-Based Cognitive Therapy, Acceptance and Commitment Therapy, and Positive Psychotherapy for Major Depression. American Journal of Psychotherapy. 2021.
  10. ↑ Kuyken W, Warren FC, Taylor RS; et al. (2016). "Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials". JAMA Psychiatry. 73 (6): 565–574. doi:10.1001/jamapsychiatry.2016.0076.
  11. ↑ DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020.
  12. ↑ 12.0 12.1 Park LT, Zarate CA Jr. Depression in the Primary Care Setting. N Engl J Med. 2019.
  13. ↑ Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA (2019). "Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis". JAMA Psychiatry. 76 (7): 700–707. doi:10.1001/jamapsychiatry.2019.0268.
Retrieved from "https://www.wikidoc.org/index.php?title=Major_depressive_disorder_psychotherapy&oldid=1746767"